TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1479656

Group type: EXPERIMENTAL
Intervention: 2 sheets of nitroglycerin patches (5 mg each)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 5 sheets of nitroglycerin patches (5 mg each)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10 sheets of nitroglycerin patches (5 mg each)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 0 sheets of nitroglycerin patches (control group)
Number of subjects: 29
Study: 6703268

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bupivacaine and Prilocaine (increased dose)
Number of subjects: 6
Study: 30191249

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine arm (LBA) - 20 ml 1.3% bupivacaine liposomal mixed with 10 ml 0.5% bupivacaine at the sacrospinous ligament.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Lidocaine arm (LA) - 30 ml 0.5% lidocaine with 1:200,000 epinephrine local injection at the sacrospinous ligament.
Number of subjects: 37
Study: 29665097

Group type: EXPERIMENTAL
Intervention: Elbasvir-grazoprevir for 12 weeks
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Elbasvir-grazoprevir for patients with Stage 4 or 5 chronic kidney diseases
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Intent-to-treat with elbasvir-grazoprevir
Number of subjects: 470
Study: 26848802

Group type: EXPERIMENTAL
Intervention: MS-10 for 90 days
Number of subjects: 0
Study: 25522396

Group type: EXPERIMENTAL
Intervention: Escitalopram (ESC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30
Study: 23171588

Group type: EXPERIMENTAL
Intervention: Early surgical evacuation of the haematoma
Number of subjects: 601

Group type: COMPARATOR
Intervention: Initial conservative treatment
Number of subjects: 601
Study: 19159999

Group type: EXPERIMENTAL
Intervention: Nifedipine sustained release (nifedipine SR)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ginkgo biloba extract
Number of subjects: 93
Study: 17353373

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD) 0.4 mg/kg administered orally 3 times per day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD)
Number of subjects: 12
Study: 14732641

Group type: EXPERIMENTAL
Intervention: Oral and written communication about the risks of the procedure (pamphlet)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral communication about the risks of the procedure (no pamphlet)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral and written communication (pamphlet)
Number of subjects: 120
Study: 11568067

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 72
Study: 9563071

Group type: EXPERIMENTAL
Intervention: Saquinavir under fed conditions
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saquinavir under fasted conditions
Number of subjects: 8
Study: 7519062

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 200/0.5 (HES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% human albumin (HA5)
Number of subjects: 40
Study: 2742290

Group type: EXPERIMENTAL
Intervention: Atropine 1% eye drops every other night
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1% eye drops every night
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline eye drops every night
Number of subjects: 96
Study: 31381494

Group type: EXPERIMENTAL
Intervention: Water-soluble chicken eggshell membrane (WSEM) 450 mg daily
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 28915284

Group type: EXPERIMENTAL
Intervention: ET handpiece (small spot size)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HSS handpiece (large spot size, single pass)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HSD handpiece (large spot size, double pass)
Number of subjects: 13
Study: 26113098

Group type: EXPERIMENTAL
Intervention: CEREC VITABLOCS Mark II
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IPS Empress CAD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IPS e.max CAD
Number of subjects: 60
Study: 23035749

Group type: EXPERIMENTAL
Intervention: six 4‐mg doses of betamethasone every 8 h
Number of subjects: 121

Group type: COMPARATOR
Intervention: two 12‐mg doses of betamethasone separated by 24 h
Number of subjects: 121
Study: 21799914

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 1478

Group type: COMPARATOR
Intervention: Control (no acyclovir)
Number of subjects: 1478
Study: 19384914

Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Fields (PEMFs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16436398

Group type: EXPERIMENTAL
Intervention: Ads sponsored by Philip Morris or Lorillard
Number of subjects: 832

Group type: COMPARATOR
Intervention: Ads from the American Legacy Foundation
Number of subjects: 832

Group type: COMPARATOR
Intervention: Ads about preventing drunk driving
Number of subjects: 832
Study: 15652545

Group type: EXPERIMENTAL
Intervention: Inverted orthotic
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Standard orthotic
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: No orthotic
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 11
Study: 12002834

Group type: COMPARATOR
Intervention: occlusal splints (group I)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: occlusal splints and supplementary medical therapy (group II)
Number of subjects: 72

Group type: COMPARATOR
Intervention: occlusal splints and physical therapy (group III)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: occlusal splints, medical, and physical therapy (group IV)
Number of subjects: 72
Study: 10207532

Group type: EXPERIMENTAL
Intervention: Chlorhexidine/thymol-containing dental varnish (Cervitec)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo varnish without active ingredients
Number of subjects: 15
Study: 7796342

Group type: EXPERIMENTAL
Intervention: Single beam DXA scans
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fan beam DXA scans
Number of subjects: 36
Study: 2223143

Group type: EXPERIMENTAL
Intervention: Oral melphalan (0.25 mg/kg/day) with oral prednisone (2 mg/kg/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intravenous melphalan (0.125 mg/kg/day) with oral prednisone (2 mg/kg/day)
Number of subjects: 81
Study: 333855

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg - 40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 20
Study: 29271835

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Strength Exercise (SE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 10
Study: 28538781

Group type: EXPERIMENTAL
Intervention: Passive cycling exercise combined with conventional physical therapy (5 days per week)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Passive cycling exercise combined with conventional physical therapy
Number of subjects: 38
Study: 25475930

Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA)
Number of subjects: 4061

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 4061
Study: 23107931

Group type: EXPERIMENTAL
Intervention: web‐based expert system (QuitCoach)
Number of subjects: 3530

Group type: EXPERIMENTAL
Intervention: text messaging program (onQ)
Number of subjects: 3530

Group type: EXPERIMENTAL
Intervention: both as an integrated package
Number of subjects: 3530

Group type: COMPARATOR
Intervention: control condition informed of a static website
Number of subjects: 3530
Study: 20925442

Group type: EXPERIMENTAL
Intervention: Vardenafil ODT (10 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vardenafil FCT (film-coated tablet)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vardenafil ODT with food
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vardenafil ODT in men aged ≥65 years
Number of subjects: 3
Study: 19047077

Group type: EXPERIMENTAL
Intervention: Maternal CD4 count <200 during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Earlier breastfeeding cessation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low CD4 count
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional Cox proportional hazards model
Number of subjects: 0
Study: 17298968

Group type: EXPERIMENTAL
Intervention: Thrombolysis (TL) in community hospital
Number of subjects: 850

Group type: COMPARATOR
Intervention: Interhospital transfer for primary percutaneous coronary intervention (p-PCI)
Number of subjects: 850
Study: 15114797

Group type: EXPERIMENTAL
Intervention: Adult learning theory-based curriculum (PG)
Number of subjects: 0
Study: 11554127

Group type: EXPERIMENTAL
Intervention: Azathioprine 100 mg/day for 6 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 33

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 33
Study: 9630326

Group type: EXPERIMENTAL
Intervention: CsA at a dosage of 1 mg/kg/die (CsA1)
Number of subjects: 59

Group type: COMPARATOR
Intervention: CsA at a dosage of 3 mg/kg/die (CsA3)
Number of subjects: 59
Study: 7834056

Group type: EXPERIMENTAL
Intervention: Saliva from healthy individuals
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saliva from patients with periodontal disease
Number of subjects: 35
Study: 3050268

Group type: EXPERIMENTAL
Intervention: High NaCl diet (20 g/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low NaCl diet (2 g/day)
Number of subjects: 15
Study: 31783267

Group type: EXPERIMENTAL
Intervention: Mobile community learning (MCL) programme in case management (CM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 48
Study: 30928294

Group type: EXPERIMENTAL
Intervention: Individualized perioperative ventilatory strategy (intraoperative recruitment maneuvers, individualized positive end-expiratory pressure, postoperative high-flow nasal cannula)
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Conventional lung-protective ventilation
Number of subjects: 1380
Study: 29354989

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 61

Group type: COMPARATOR
Intervention: Western medication (Pinaverium bromide tablet, 50 mg, 3 times a day)
Number of subjects: 61
Study: 25230980

Group type: EXPERIMENTAL
Intervention: Polypill (hydrochlorothiazide, aspirin, atorvastatin, and either enalapril or valsartan)
Number of subjects: 8410

Group type: COMPARATOR
Intervention: Minimal care (non-pharmacological preventive interventions)
Number of subjects: 8410
Study: 23360891

Group type: EXPERIMENTAL
Intervention: PhysioDirect services
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1506
Study: 22050134

Group type: EXPERIMENTAL
Intervention: 100 rpm group
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50 rpm group
Number of subjects: 20
Study: 18811828

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch solution 130/0.42 (HES)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4% modified fluid gelatin (GEL)
Number of subjects: 50
Study: 16543549

Group type: EXPERIMENTAL
Intervention: Medical therapy arm of the National Emphysema Treatment Trial
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Oxygen utilization
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Total lung capacity % predicted
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Residual volume % predicted
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Maximal cardiopulmonary exercise testing workload
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Proportion of emphysema in the lower lung zone versus the upper lung zone
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Upper‐to‐lower‐lung perfusion ratio
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Modified BODE index
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: FEV1
Number of subjects: 609
Study: 12767651

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 103

Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 103

Group type: COMPARATOR
Intervention: ICD
Number of subjects: 103
Study: 10694609

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 9384477

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with carmustine (300 mg/m2 x 1), etoposide (150 mg/m2 twice a day x 4 days), cytarabine (100 mg/m2 twice a day x 4 days), and cyclophosphamide (35 mg/kg x 4 days) followed by infusion of unmanipulated PBSC.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with PBSC infusion for patients who had failed primary induction chemotherapy (28 patients).
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with PBSC infusion for patients in untreated first relapse (27 patients).
Number of subjects: 83

Group type: COMPARATOR
Intervention: High-dose chemotherapy (HDC) with PBSC infusion for patients who had reinduction attempts prior to receiving mobilization chemotherapy (18 patients).
Number of subjects: 83
Study: 1585757

Group type: EXPERIMENTAL
Intervention: Micanol (new dithranol formulation)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Dithranol 1% in petrolatum
Number of subjects: 59

Group type: COMPARATOR
Intervention: Dithranol 1% in Amitase stick
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 4004200

Group type: EXPERIMENTAL
Intervention: Succinate limitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other limitation (possibly sulphate limitation)
Number of subjects: 0
Study: 30575682

Group type: EXPERIMENTAL
Intervention: High-salt diet (>12 g/day) with NTG
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-salt diet (>12 g/day) without NTG
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-salt diet (<3 g/day) with NTG
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-salt diet (<3 g/day) without NTG
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-salt diet (>12 g/day) with large body weight change
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-salt diet (>12 g/day) with small body weight change
Number of subjects: 18
Study: 28840638

Group type: EXPERIMENTAL
Intervention: Walking combined with resting
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Walking combined with balneotherapy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined resting and balneotherapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Resting only
Number of subjects: 81
Study: 26498451

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment
Number of subjects: 30
Study: 24825768

Group type: EXPERIMENTAL
Intervention: Doxycycline in Group 1 (40 patients)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Doxycycline in Group 2 (15 patients)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard therapy in Group 1 (37 patients)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard therapy in Group 2 (18 patients)
Number of subjects: 110
Study: 22687786

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg/day
Number of subjects: 40
Study: 20664537

Group type: EXPERIMENTAL
Intervention: Oltipraz (30-90 mg single dose; 60 mg b.i.d. or 90 mg q.d. for 24 weeks)
Number of subjects: 0
Study: 18034258

Group type: EXPERIMENTAL
Intervention: Coblator
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bipolar scissors
Number of subjects: 40
Study: 15639067

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 800 mug
Number of subjects: 10

Group type: COMPARATOR
Intervention: Buccal misoprostol 800 mug
Number of subjects: 10
Study: 12048051

Group type: EXPERIMENTAL
Intervention: Functional transcranial Doppler sonography
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Line bisection task
Number of subjects: 20
Study: 11476263

Group type: EXPERIMENTAL
Intervention: Continuing education workshops for rating-scale training (4 different workshops)
Number of subjects: 27
Study: 9129767

Group type: EXPERIMENTAL
Intervention: LDL apheresis (Liposorber system, Kanegafuchi Chemical Industrial Company LTD, Osaka, Japan)
Number of subjects: 2
Study: 8435265

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg kg-1
Number of subjects: 102

Group type: COMPARATOR
Intervention: Thiopentone 5 mg kg-1
Number of subjects: 102
Study: 2448425

Group type: EXPERIMENTAL
Intervention: 10% hydroxyethylstarch (HES), 500 ml daily for 7 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group without HES infusion
Number of subjects: 27
Study: 29924703

Group type: EXPERIMENTAL
Intervention: Protein-enhanced diet (1.2 g protein/kg body weight/day with 30 g protein/meal), n=41
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control diet (0.8 g protein/kg body weight/day), n=21
Number of subjects: 67
Study: 27977890

Group type: EXPERIMENTAL
Intervention: Scissor-type knife supported WJ needle-knife (SB Jr group)
Number of subjects: 85

Group type: COMPARATOR
Intervention: WJ needle-knife alone (Flush group)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 26850888

Group type: EXPERIMENTAL
Intervention: Optimized group 1 (individualized treatment in 30 DM cases)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Retreatment group 1 (standard retreatment regimen in 30 DM cases)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Optimized group 2 (individual regimen in 57 non-DM cases)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Retreatment group 2 (standard retreatment regimen in 61 non-DM cases)
Number of subjects: 178
Study: 23298380

Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 0
Study: 21636239

Group type: EXPERIMENTAL
Intervention: Protégé EverFlex 200-mm-long self-expanding nitinol stent
Number of subjects: 100
Study: 18974579

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (300 mg with each dialysis session)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 132
Study: 16492717

Group type: EXPERIMENTAL
Intervention: Fontolizumab 0.1 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fontolizumab 1.0 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fontolizumab 4.0 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fontolizumab (all doses)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 14656778

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethylstarch (HES 130/0.4)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lactated Ringers solution (RL)
Number of subjects: 36
Study: 10840987

Group type: EXPERIMENTAL
Intervention: Tomato juice (500 ml/day)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 U/day)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 9412748

Group type: EXPERIMENTAL
Intervention: sodium hypochlorite 0.25% (SH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: iodine 1% in ethanol 70% (IE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: chlorhexidine 4% (CH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: chlorhexidine 0.5% in ethanol 70% (CE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ethanol 70% (ET)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: povidone‐iodine 10% (PI)
Number of subjects: 20
Study: 8466723

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 883

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 883
Study: 30389027

Group type: EXPERIMENTAL
Intervention: 0.250 × 10^6 Df‐C per kg/BW
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5 × 10^6 Df‐C per kg/BW
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 × 10^6 Df‐C per kg/BW
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 28854883

Group type: EXPERIMENTAL
Intervention: Peg‐IFNα‐2a + entecavir (ETV)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Peg‐IFNα‐2a + adefovir dipivoxil (ADV)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Peg‐IFNα‐2a (control)
Number of subjects: 178
Study: 23879615

Group type: EXPERIMENTAL
Intervention: Immediate functional loading implants (test group 1) with conventional drilling procedure
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Immediate functional loading implants (test group 2) with modified implant installation procedure (osteotome technique)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Conventional drilling procedure with submerged implants for 3 months (control group)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: All implants (combined data)
Number of subjects: 151
Study: 24348619

Group type: EXPERIMENTAL
Intervention: Infiltration technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: I.A nerve block
Number of subjects: 40
Study: 21951832

Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg qd
Number of subjects: 1021

Group type: COMPARATOR
Intervention: sulphonylurea
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: sitagliptin and sulphonylurea
Number of subjects: 1021
Study: 18165450

Group type: EXPERIMENTAL
Intervention: Long chain triglycerides (LCT) infusion for 5 days postoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no LCT infusion)
Number of subjects: 60
Study: 17198491

Group type: EXPERIMENTAL
Intervention: Experimental nutritional formula (EXP) 240 mL/d for 4 weeks before and 6 weeks after influenza vaccination
Number of subjects: 157
Study: 14528469

Group type: EXPERIMENTAL
Intervention: Antegrade AoI net blood flow (Group 1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Retrograde AoI net blood flow (Group 2)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72